Statins Significantly Cut Heart Event Risk in Healthy Seniors Over 70

A major study published in the New England Journal of Medicine, the STAREE trial conducted in Australia, has provided significant evidence that statin treatment can reduce the risk of major cardiovascular events in individuals aged 70 and older who have no known cardiovascular disease. The randomized, double-blind, placebo-controlled trial involved nearly 10,000 participants with an average age of 75. Half received 40 mg of atorvastatin daily, while the other half received a placebo, with a median follow-up of 5.9 years.

The study found that atorvastatin reduced the relative risk of a significant cardiovascular event, including cardiovascular death, non-fatal heart attack, stroke, or the need for arterial procedures, by 30%. Events occurred in 6% of the atorvastatin group compared to 8.3% in the placebo group. Professor Eyal Ben-Assa, Director of Invasive Cardiology at Assuta Ashdod Hospital, highlighted the importance of this research for an older, independent population without pre-existing conditions, stating it provides strong scientific backing for initiating statins for primary prevention in this age group.

While the STAREE trial met its primary cardiovascular endpoint, it did not show a statistically significant reduction in the secondary endpoint of "disability-free life," which included death from any cause, dementia, or persistent physical disability. However, a separate observational study from Denmark, presented at the European Society of Cardiology congress and published in The Lancet Regional Health, Europe, suggested a potential link between earlier statin initiation in type 2 diabetes patients and a reduced risk of developing dementia over ten years. This Danish study indicated a 15% lower relative risk for those starting statins within a year of diagnosis compared to non-starters.

Professor Ben-Assa cautioned that the findings do not imply universal statin use for everyone over 70, emphasizing the need for individualized treatment based on risk factors and overall health. He also noted that while statins may not directly prevent all types of dementia, they could indirectly benefit brain health by preventing strokes, particularly vascular dementia. The consensus is that while statins are not a cure for dementia, the research provides greater confidence in using them for primary cardiovascular prevention in active seniors over 70.